|
Synonyms: ATRN-119 | ATRN119 | compound P(4) [US20170226130]
Compound class:
Synthetic organic
Comment: Mosipasertib is the INN for a serine/threonine kinase inhibitor with antineoplastic potential that was included in WHO INN Proposed List 135 (July 2026). Structure matches exist in patents that claim macrocyclic ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors that are held by Atrin Pharmaceuticals [2], whose lead asset was the orally bioavailable ATR inhibitor ATRN-119. Atrin Pharmaceuticals was subsequently acquired by Aprea Therapeutics. The code name-to-INN association is confirmed on Aprea's pipeline webpage [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Aprea.
Aprea is focused on delivering breakthrough therapies for cancers with high unmet medical need. Our two lead programs are WEE1 inhibitor (APR-1051) and ATR inhibitor (ATRN-119). Accessed on 29/07/2026. Modified on 29/07/2026. https://aprea.com, https://aprea.com/aprea-therapeutics-pipeline/ |
|
2. Breslin HJ, Gilad O. (2017)
Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase Inhibitors. Patent number: US20170226130A1. Assignee: Atrin Pharmaceuticals LLC. Priority date: 27/04/2017. Publication date: 10/08/2017. |
|
3. Hansbarger MM, Rocca SJ, Gill T, Breslin H, Jia L, George EM, Rom I, Lee T, Weinstein J, Simpkins F, Brown EJ et al.. (2025)
Abstract 2907: A first-in-class series of potent and selective macrocyclic ATR inhibitors. Cancer Res, 85 (8_Supplement_1): 2907. DOI: 10.1158/1538-7445.AM2025-2907 |